An observational study in Colorectal Cancer, Gastro-oesophageal Adenocarcinoma and Hepato-Biliary Carcinoma in Situ Nos, sponsored by Royal Marsden NHS Foundation Trust. Not yet recruiting. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
Among 22 studies in Colorectal Neoplasms by Royal Marsden NHS Foundation Trust — 3 open to participants now, 4 under way, none of them phase 3. Colorectal Neoplasms · Royal Marsden NHS Foundation Trust.
Among the 22 studies in Colorectal Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is the only one that started in 2026, is one of 12 observational ones, and was the 22nd registered.
6,541 studies on the registry are indexed under Colorectal Neoplasms; 1,667 are open to participants now.
Browse Colorectal Neoplasms studies →3 of the 22 studies in Colorectal Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 1 country. Recruiting first, the newest first:
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
By country, each count listing its studies:
Of the 1,185 Colorectal Neoplasms studies recruiting now, 769 (65%) set no upper age limit and 265 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 250 across 1,440 observational studies indexed under Colorectal Neoplasms.
Median enrollment 88 across the 10 interventional studies, 138 across the 12 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Royal Marsden NHS Foundation Trust is the lead sponsor of 273 studies on the registry; 53 are open to participants now.
1 of the studies in Colorectal Neoplasms by Royal Marsden NHS Foundation Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07673861Royal Marsden NHS Foundation TrustClinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients | 2026-12-31 |
Among the 22 studies in Colorectal Neoplasms by Royal Marsden NHS Foundation Trust, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to better understand how gastrointestinal (digestive system) cancers develop and how they respond to treatment in young adults, in order to improve ways to prevent, diagnose, and manage these cancers in this age group.
This prospective study is designed to establish a database of young adult patients diagnosed with gastro-intestinal malignancies, with availability of matched clinical data and biological samples including but not limited to tumour tissue. This will serve as a valuable platform to sub studies and collaboration with national and international groups, to better understand the pathogenesis of cancers in this unique cohort and to better tailor treatment to maximise efficacy and minimise toxicity. The analysis plan will develop as the study progresses. At the outset, three areas of interest for investigation are molecular profiling of the tumour and it's microenvironment, the intestinal microbiome and collaboration with groups developing patient derived organoids and metabolomics. It may also provide a platform for future longitudinal research to identify long term health trends.
Patients must be receiving treatment at The Royal Marsden NHS Foundation Trust.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Cohort A: Colorectal Cancer including at least 20 patients with appendiceal cancer.
4. Patient being treated at the Royal Marsden Hospital.
Exclusion Criteria:
Patients with a history another of malignancy with within 2 years, excluding resected non melanomatous skin cancers.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients aged under 50 with colorectal cancer (including at least 20 patients with appendiceal cancer)
Biological: Research blood samples
Patients aged 18-50 with gastro-oesophageal cancer
Biological: Research blood samples
Patients aged 18-50 with Hepato-biliary cancer.
Biological: Research blood samples
Sample taken at baseline, 8-12 weeks post first treatment commencement and at first disease progression or relapse.
Establishment of a prospective early-onset gastrointestinal cancer cohort and biorepositor
Number of participants recruited to the cohort with linked biospecimen collection, clinical data capture, and longitudinal follow-up completed according to protocol.
Time frame: 5 years
Lifestyle, dietary, environmental, and early-life exposures
Characterisation of lifestyle, dietary, environmental, and early-life factors and their association with cancer subtype, molecular characteristics, disease stage, and clinical outcomes.
Time frame: Baseline and up to 5 years follow-up
Gut microbiome characteristics
Association between gut microbiome composition and tumour characteristics, treatment response, disease progression, and survival outcomes.
Time frame: Baseline and up to 5 years follow-up
Circulating biomarkers and translational research markers
Changes in patient-reported quality of life following diagnosis and treatment of early-onset gastrointestinal cancer, as measured using validated questionnaires.
Time frame: Baseline and up to 5 years follow-up
Development of patient-derived in vivo models
Proportion of collected tumour samples successfully used to establish and characterise patient-derived animal models.
Time frame: up to 5 years.
Development of patient-derived organoid models
Proportion of collected tumour samples successfully used to establish and characterise patient-derived organoid models for translational research studies.
Time frame: up to 5 years
No study locations are listed for this record.
Plan to share: Undecided — Undecided at present
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2031, 60 months later.
Of 528 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 60 months is close to that.
Counting every sponsor, half of 645 studies reached it within 51 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust →